Crizotinib has shown strong anti-tumor activity against relapsed/refractory ALK+ ALCL.[10,11] A CR was observed in 83% of the relapsed/refractory ALK+ ALCL patients who received 165 mg/m2 of crizotinib and in 80% of the patients who received 280 mg/m2. The gene discussed is ALK; the disease is neoplasm.